Evolus, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Accelerated filer
State of Incorporation
DE
Business Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH, CA, 92660
Mailing Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH, CA, 92660
Phone
(949) 284-4555
Fiscal Year End
1231
EIN
461385614
Financial Overview
FY2025
$248.97M
Total Liabilities
$-0.80
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | March 18, 2026 | View on SEC |
| 8-K Current report of material events | March 13, 2026 | View on SEC |
| 8-K Current report of material events | March 3, 2026 | View on SEC |
| 10-K Annual financial report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
Annual Reports
10-K
March 3, 2026
- Achieved 28% revenue growth to $205 million in 2025.
- Successfully launched Evolysse dermal fillers internationally, diversifying its product portfolio.
Insider Trading
STRONG SELL
2 insiders
6 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.